by Duncan Fisher

September 02, 2022 - 2 min read

There is evidence of interaction between the body’s widespread endocannabinoid and monoamine neurotransmitter systems in regulation of compulsive behavior. Cannabidiol (CBD) has been shown in animal models to inhibit obsessive-compulsive behaviour, in a time-dependent manner, matching its pharmacokinetic profile.

The mechanisms of action behind this are beginning to be understood. Cannabinoid receptors are significantly expressed in most parts of the cortico-striatal-thalamic circuitry, the network related to OCD, where they are able to modulate the release of key neurotransmitters such as glutamate, dopamine, GABA, and serotonin. Preclinical studies show that enhancement of cannabinoid receptor site 1 (CB1) function by direct agonists or inhibitors modulates compulsive activity. Deletion of CB1 receptors prevents shifting from goal-directed to habitual behavior. Inhibition of endocannabinoid catabolic enzymes also elicits anxiolytic effects. Endocannabinoid analogues exacerbate compulsion in mice via the TRPV1 receptor.

A murine model has shown that CBD induces a significant decrease in the number of buried marbles compared with controls. A larger decrease was also found after co-administration of paroxetine and diazepam. The effect of the CBD was still significant after 7 days of daily repeated administration, even after the effect of the diazepam disappeared. Pretreatment with WAY100635, a 5HT1A receptor antagonist, prevented the effects of paroxetine but failed to alter those of CBD. These latter effects, however, were prevented by pretreatment with the CB1 receptor antagonist AM251.

DiolPure products contain PureForm CBD™ transformed from aromatic terpenes for pharmaceutical-grade purity. PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis, but free of any residual cannabinoids like THC or impurities or chemicals that can associate with traditional plant-derived production processes. 

The foregoing is a report on trends and developments in cannabinoid industry research. No product description herein is intended as a recommendation for diagnosis, treatment, cure or prevention of any disease or syndrome. 

Cannabigerol (CBG): Another promising cannabinoid?

Cannabigerol (CBG): Another promising cannabinoid?

For some good reasons, research and commercial attention is beginning to turn to cannabigerol, or 'CBG'. 
Read More

October 04, 2022 2 min read

Up close: Cannabinoids in Huntington's chorea

Up close: Cannabinoids in Huntington's chorea

In vitro and in vivo models of Huntington's disease, an inherited condition in which nerve cells in the brain break down over time, show disease-related alterations in the endocannabinoid system, part of the body’s neural cell-signaling network, and the dopamine regulatory system downstream. 
Read More

October 03, 2022 3 min read

Up close: Cannabinoids in neurodegenerative diseases

Up close: Cannabinoids in neurodegenerative diseases

Modulation of cannabinoid receptor signaling should represent a viable therapeutic target in neurodegenerative diseases. 
Read More

September 30, 2022 2 min read

Follow us on Instagram

Net Orders Checkout

Item Price Qty Total
Subtotal $ 0.00

Shipping Address

Shipping Methods